Search Results - therapeutics+%3e+cns+and+neurology

109 Results

Sort By:

Novel Biomarkers for Sanfilippo Syndrome (UCLA Case No. 2024-150)

UCLA researchers from the Department of Neurology have identified novel biomarkers of Sanfilippo Syndrome, leading to potential minimally invasive methods to detect Sanfilippo Syndrome and assess clinical trial outcomes. More information to follow. Contact UCLA Technology Development Group if you would like to learn more in the meantime.

Published: 7/14/2026 | Inventor(s): Gal Bitan

Keywords(s):

Category(s): Therapeutics > CNS and Neurology, Therapeutics > Metabolism And Endocrinology, Diagnostic Markers > Targets And Assays

Microbial de Novo Biosynthesis of Rare Cannabinoids (UCLA Case No. 2025-200)

UCLA researchers in the department of Chemical and Biomolecular Engineering have developed a microbial de novo biosynthesis platform that enables scalable production of rare cannabinoids with enhanced receptor affinity from simple sugar feedstocks. BACKGROUND: Cannabinoids are bioactive natural products that interact with the human endocannabinoid...

Published: 7/14/2026 | Inventor(s): ikechukwu okorafor, Yi Tang

Keywords(s):

Category(s): Therapeutics > Cardiovascular, Therapeutics > CNS and Neurology, Materials > Fabrication Technologies, Chemical > Synthesis, Chemical > Chemical Processing & Manufacturing

Enhanced Therapeutic Effect of Armored CAR-T Cells for the Treatment of Glioblastoma (UCLA Case No. 2024-066)

UCLA researchers from the Department of Microbiology, Immunology, and Molecular Genetics have engineered chimeric antigen receptor (CAR)-T cells that co-express defined immunostimulatory cytokines to enhance therapeutic efficiency against glioblastoma (GBM). BACKGROUND: Glioblastoma Multiforme (GBM) is the most common primary malignant brain tumor...

Published: 7/14/2026 | Inventor(s): Yvonne Chen

Keywords(s):

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy, Therapeutics > CNS and Neurology

UCHL1 Inhibitors, Modifications, and Uses Thereof (UCLA Case No. 2026-123)

UCLA researchers in the Department of Molecular & Medical Pharmacology and have developed novel, highly potent small-molecule inhibitors of UCHL1 that selectively suppress tumor growth and metastasis in aggressive cancers with favorable in vivo safety profiles. BACKGROUND: Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) is a dual-function enzyme...

Published: 7/14/2026 | Inventor(s): Tanya Stoyanova, Michael Jung

Keywords(s):

Category(s): Diagnostic Markers > Cancer, Therapeutics > Oncology, Therapeutics > CNS and Neurology, Therapeutics > Oncology > Oncology (Small Molecules)

Engineered Gamma Delta T-Cells and Methods of Making and Using Thereof (UCLA Case No. 2020-913)

UCLA researchers in the Department of Molecular Immunology & Molecular Genetics have developed gamma delta (gd) T cell receptor gene-modified immune cells derived from stem and progenitor cells that enable scalable, off-the-shelf allogeneic cell therapies with broad therapeutic potential. BACKGROUND: Cell-based immunotherapies have demonstrated...

Published: 7/14/2026 | Inventor(s): Lili Yang, Derek Lee, Tyler Halladay

Keywords(s):

Category(s): Diagnostic Markers > Immunology, Diagnostic Markers > Cancer, Life Science Research Tools > Cell Lines, Therapeutics > Oncology, Therapeutics > CNS and Neurology, Therapeutics > Hematology, Therapeutics > Autoimmune, Therapeutics > Gene Therapy And Editing, Therapeutics > Stem Cells And Regenerative Medicine, Therapeutics > Infectious Diseases

NPEPPS Enhancers for Treating Tau-Induced Neurodegeneration (UCLA Case No. 2018-161)

UCLA researchers from the Department of Neurology have developed first-in-class small-molecule activators of NPEPPS that effectively lower pathological tau, offering a novel disease-modifying strategy for Alzheimer’s and other neurodegenerative disorders. BACKGROUND: Neurodegenerative dementias such as Alzheimer’s Disease (AD) and progressive...

Published: 7/14/2026 | Inventor(s): Daniel Geschwind, Robert Damoiseaux, Liting Deng, Michael Jung, Jennifer Murphy, Gaoyuan Ma

Keywords(s):

Category(s): Therapeutics > CNS and Neurology, Diagnostic Markers > Targets And Assays

Brain Repair in Vascular Dementia and Stroke with A3AR (UCLA Case No. 2024-220)

UCLA researchers from the Department of Neurology have discovered and validated intercellular signaling pathways that can be therapeutically targeted to drive repair and functional recovery in vascular dementia. BACKGROUND: Vascular dementia (VaD) is the second leading cause of dementia and is driven by ischemic injury to cerebral white matter, producing...

Published: 7/14/2026 | Inventor(s): Stanley Carmichael

Keywords(s):

Category(s): Therapeutics > CNS and Neurology, Therapeutics > Cardiovascular, Life Science Research Tools > Animal Models

Directed Differentiation Protocols to Derive Bone Fide Spinal Sensory Interneurons (UCLA Case No. 2022-224)

UCLA researchers from the Department of Neurobiology have developed innovative protocols to differentiate and expand spinal sensory interneurons for drug discovery and to utilize in cell replacement therapies to restore injured spinal cords. BACKGROUND: Spinal cord injuries (SCIs) can result in the loss of controlled movement and somatosensation, the...

Published: 7/14/2026 | Inventor(s): Samantha Butler

Keywords(s):

Category(s): Life Science Research Tools > Research Methods, Therapeutics > Stem Cells And Regenerative Medicine, Therapeutics > CNS and Neurology

Broad-Band Frequency Repetitive Transcranial Magnetic Stimulation for the Treatment of Neuropsychiatric Disorders (Case No. 2025-99J)

Summary: Researchers in UCLA's Semel Institute and Department of Psychiatry have developed an innovative approach to treating depression by optimizing repetitive Transcranial Magnetic Stimulation (rTMS), improving its effectiveness for the treatment of Major Depressive Disorder (MDD) and possibly diseases of the mind and brain. Background: Depression...

Published: 7/14/2026 | Inventor(s): Andrew Leuchter, Juliana Corlier, Thomas Valles

Keywords(s): Bioelectromagnetics, Brain, Deep Brain Stimulation, Electrical Brain Stimulation, energy-efficient, frequency modulation, Magnetic Field, Medical Device, medication efficacy, neural information, neural network, neural networks, neural signals, neural stimulation, neurobehavioral impairment, Neurocognitive, neurological disorders, Neuromodulation, Neuron, neurons, neuroscience, Neurostimulation, pulsed load modulation, therapy, treatment efficacy

Category(s): Medical Devices, Medical Devices > Neural Stimulation, Life Science Research Tools, Therapeutics > CNS and Neurology, Therapeutics

Antiviral Compounds Inhibiting Zika Virus (ZIKV), and Methods and Zika Treatment Thereof (UCLA Case No. 2025-241)

UCLA researchers from the Molecular and Medical Pharmacology Department and CNSI have identified antiviral compounds that effectively inhibit Zika virus infection and cytopathic effects, potentially leading to improved therapeutics and treatment outcomes. BACKGROUND: Zika virus (ZIKV), a flavivirus now endemic to several regions globally, can cause...

Published: 7/14/2026 | Inventor(s): Vaithilingaraja Arumugaswami, Robert Damoiseaux

Keywords(s):

Category(s): Life Science Research Tools > Screening Libraries, Diagnostic Markers > Immunology, Diagnostic Markers > Targets And Assays, Therapeutics > Infectious Diseases, Therapeutics > CNS and Neurology, Therapeutics > Immunology And Immunotherapy, Platforms > Diagnostic Platform Technologies

1 2 3 4 5 6 7 8 9 10 ...